Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
MindMed logo — MindMed is a clinical-stage biopharma company developing nov...

MindMed

MindMed is a clinical-stage biopharma company developing novel products to treat brain health disorders

Founded 2019 United States New York, United States 103 employees Post-IPO Equity Total: $377.63M Biotechnology, Health Care +1

General Information

Company Name MindMed
Founded Year 2019
Location United States New York, United States
Founders / Decision Makers
Team member Team member Team member Team member
Employees 103
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with MindMed. To contact MindMed, visit mindmed.co.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MindMed compare?

A PDF of MindMed and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MindMed soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MindMed

MindMed is a clinical-stage biopharmaceutical company founded in 2019 with a mission to address brain health disorders, focusing on psychiatry, addiction, pain, and neurology. The company aims to be a global leader in developing and delivering treatments to improve patient outcomes. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. The company has received a significant $175.00M Post-IPO Equity investment on 07 March 2024 from a consortium of investors including Marshall Wace, Ally Bridge Group, Commodore Capital, Deep Track Capital, Driehaus Capital Management, Janus Handerson, Octagon Capital Advisors, Soleus Capital, Woodline Partners, and Great Point Partners. MindMed's focus on innovative drug candidates targeting the serotonin, dopamine, and acetylcholine systems places it at the forefront of biotechnology, healthcare, and pharmaceutical industries, showcasing its potential to address unmet medical needs and drive advancements in brain health treatments.

Business keywords: biopharmaceutical, clinical-stage, psychiatry, addiction treatment, neurology, serotonin, dopamine, acetylcholine, psychedelic medicines, substance abuse disorders, drug development pipeline, NASDAQ, NEO Exchange, Psilocybin, LSD

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $175.00M 10
Marshall Wace Commodore Capital Deep Track Capital
Marshall Wace, Commodore Capital +8
07 Mar 2024
Post IPO Debt $15.00M 1
K2 HealthVentures
K2 HealthVentures
14 Aug 2023
Post IPO Equity $30.00M -
27 Sep 2022
Post IPO Equity $15.40M 1
Canaccord Genuity Group
Canaccord Genuity Group
08 Mar 2021
Post IPO Equity $72.00M 3
Canaccord Genuity Group CIBC Innovation Banking Eight Capital
Canaccord Genuity Group, CIBC Innovation Banking +1
14 Dec 2020
Pre Seed Round Undisclosed 1
Talent Resources Ventures
Talent Resources Ventures
26 Oct 2020
Post IPO Equity $27.00M 2
Canaccord Genuity Group Eight Capital
Canaccord Genuity Group, Eight Capital
09 Oct 2020
Post IPO Equity $13.23M -
05 May 2020
Post IPO Equity $24.00M 1
Dan Capelle
27 Feb 2020
Post IPO Equity $6.00M 4
BT Growth Capital
BT Growth Capital, Kevin O'Leary +2
30 Sep 2019

View All 11 Funding Rounds

MindMed Alternatives & Competitors

View All Alternatives
MindMed vs
Bionomics Ltd
Bionomics Ltd Australia

Developing novel drug candidates to transform the lives of patients with anxiety and stressor-relate...

Post-IPO Equity
30 employees
Biotechnology, Health Care
Compare MindMed vs Bionomics Ltd
MindMed vs
Soligenix, Inc.
Soligenix, Inc. United States

We are a late-stage biopharmaceutical company focused on developing & commercializing products to tr...

Post-IPO Equity
27 employees
Biopharma, Biotechnology
Compare MindMed vs Soligenix, Inc.
MindMed vs
InterveXion Therapeutics
InterveXion Therapeutics United States

Binding methamphetamine to release people from addiction

Grant
6 employees
Biopharma, Biotechnology
View all alternatives

FAQ About MindMed

MindMed is a clinical-stage biopharma company developing novel products to treat brain health disorders
MindMed was founded in 2019.
MindMed is headquartered in New York, United States.
MindMed operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical, clinical-stage, psychiatry and addiction treatment.
MindMed has approximately 103 employees.
MindMed has completed 11 funding rounds, raising a total of $377.63M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to MindMed include Bionomics Ltd, Soligenix, Inc., InterveXion Therapeutics, Adial Pharmaceuticals, Addex Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MindMed and Bionomics Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MindMed, https://bouncewatch.com/company/mindmed, updated 1 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes